NCT06396065Phase 3Active not recruiting

Phase III Study of AK112 for NSCLC Patients

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2025-04-12Actual

Enrollment · participants420Actual

Source updated2026-07-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-03-03 · 3 fields changed

Participant count type changed

− Before

~~Estimated~~

+ After

Actual

Completion date type changed

− Before

~~Estimated~~

+ After

Actual

Primary completion date changed

− Before

~~31 Dec 2025~~

+ After

12 Apr 2025

Check registry source

Study details

Conditions studied

Non-Squamous Non-small Cell Lung Cancer

Treatments or interventions studied

AK112 InjectionDrugAlso known as Pemetrexed, Carboplatin
Placebo InjectionDrugAlso known as Pemetrexed, Carboplatin

Primary outcomes · main study measures

measure: Progression-free survival (PFS); description: Progression-free survival (PFS) assessed by IRC per RECIST v1.1 in the ITT population.; timeFrame: Up to 2 years; measure: Overall Survival (OS) in the ITT population; description: Overall Survival (OS) in the ITT population; timeFrame: Up to 2 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history